Metformin may lower colorectal cancer risk by stopping precancerous lesion formation

the ONA take:

Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, according to a study published online ahead of print in the journal Cancer Epidemiology, Biomarkers & Prevention.

Because previous research has suggested that metformin may lower colorectal cancer risk in patients with diabetes and most colorectal cancers originate in precancerous adenomas, researchers from Kaiser Permanente in California and the University of Pennsylvania Perelman School of Medicine sought to determine whether metformin use lowered colorectal adenoma risk following polypectomy in patients with type 2 diabetes.

Researchers retrospectively analyzed data from 2,142 patients age 40 to 89 years with type 2 diabetes, at least one adenoma at baseline colonoscopy, and at least one adenoma at repeat colonoscopy 1 to 10 years from baseline colonoscopy.

Results showed that metformin use was associated with lower adenoma recurrence risk. Researchers found that the association was stronger with increasing total metformin dose.

“Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes,” the authors conclude.

Metformin may decrease of lung cancer among nonsmokers with diabetes
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions.
Kaiser Permanente Northern California, Division of Research 2Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine 3Division of Research, Kaiser Permanente Northern California 4Division of Research, Kaiser Permanente 5Family Medicine and Community Health, University Of Pennsylvania Perelman School of Medicine ↵*Corresponding Author: Chyke A Doubeni, Family Medicine and Community Health, University Of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, Gates 2, Philadelphia, PA, 19104, United States chyke.doubeni{at}uphs.upenn.edu Background: Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer (CRC) risk.
READ FULL ARTICLE From cebp.aacrjournals.org
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs